Praveen Bommareddy
@Praveen_IO
Followers
409
Following
3K
Media
15
Statuses
340
Cancer Immunology, Oncolytic immunotherapies, IO combinations. Tweets are my personal opinion. "Proud SITC member" My personal account and my personal views!
Joined November 2017
Congratulations to @sitcancer and organizers @MyOncology (Zhen Su), Emy Chen, @KristenHege, David Kaufman, Holger Kissel, Beverly Lu, Alex Snyder and Kasia Urbanska on a tremendous #biotech Strategic Meeting. Such a great day of science and conversation towards our goal of 100
0
0
1
An informative discussion on recent FDA initiatives including Project Optimus, FrontRunner and Accelerated Approvals. Thanks to @sitcancer IO initiative.
Big thanks to the #FDA representatives for participating in the #SITC #IO Drug Development Summit today. An informative discussion on recent FDA initiatives including Project Optimus and FrontRunner. Learn more about the Summit here: #SITCquestfor100
0
0
1
Heading to @ASCO #ASC02024 Don’t miss our oral presentations in immune check point inhibitor (PD-1/+/-CTLA-4) failed melanoma and uveal melanoma. Visit to learn more about our science and clinical programs.
replimune.com
Replimune is a commercial-stage biotech company revolutionizing cancer treatment with a new class of oncolytic immunotherapies designed to activate a…
We are excited to be in Chicago for #ASCO24 to learn all about the latest and greatest advancements in #oncology – don’t miss us at Booth #16143 or at one of our presentations!
0
0
2
Happening @AACR #AACR24 hall GH, beyond immune checkpoint inhibitors #transplant $REPL RP1 onoclytic HSV-1 mono therapy ~35%% ORR in SOT recipients with CSCC and no organ rejection in patients with hepatic, renal and lung transplant
1
4
12
Great team @sitcancer #AACR24 #SITCSRC @sitcancerECS @IAmDrDex @gulleyj1 @JennGuerriero @stefanispranger @zaccoop @CentralParkWMD @DemariaLab_WCM Dr. Romero & Dr. Ribas @AACR
2
7
26
Honored to present about Oncolytic HSV-1 and @Replimune clinical and biomarker data @GustaveRoussy.
🦠 Les virus : un nouveau médicament contre le #cancer. Un sujet vaste qui sera traité le vendredi 22/03 au cours du ✨DIU virus et cancer✨ organisé à @GustaveRoussy. Plus d'information ➡
0
0
8
Looking forward to #SITC24!.
Wrapping up a hugely successful and very fun #SITC23. The @sitcancer staff did an incredible job and I’m so proud of the programming @sitcancerECS put on. Thank you to my colleagues who have become both inspiration and friends. See you next year in Houston. Next stop,
0
1
8
Please join us today at #SITC23 for the Rapid Oral Abstract- Clinical session 205b today at 12:10 PDT Hall C to @alessi_joao @MLopezdeRodas @michelle_a_tran and others .@sitcancer.@sitcancerECS.I am looking forward to chairing this session with.@DrBetofMDPhD.
0
2
4
RT @gulleyj1: Just out!.👉Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melan….
0
3
0
RT @DmitriyZamarin: Hi everyone, my lab at @IcahnInstitute and @SinaiImmunol at Mount Sinai is hiring! If you’re a motivated postdoc intere….
0
38
0
RT @rbryanbell: Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy: brilliant review from Suza….
cell.com
Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-...
0
9
0
RT @jitcancer: New #JITC article: Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multi….
0
3
0
RT @robertcoffin3: Final (five year) results for neoadjuvant T-VEC + surgery vs surgery alone in resectable advanced melanoma shows pronoun….
0
5
0
RT @jitcancer: New #JITC article: Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-re….
0
6
0
Nice interview by @bradloncar @robertcoffin3 about the development of next generation potent oncolytic immunotherapies.
Modality profile: Oncolytic Immunotherapies at #ASCO23 with Robert Coffin.
0
0
2
36% ORR and 20% CR rates in n=75 advanced melanoma pt who failed anti-PD-1+/-aCTLA-4. Responses are durable and observed across all subgroups, further RP1+nivo is very well tolerated!!.
ir.replimune.com
RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%,...
1
0
4
36% ORR in n=75 advanced melanoma pt who failed anti-PD-1+/-aCTLA-4. Responses observed across all subgroups of pt. Very well tolerated!!.
$REPL announces positive interim snapshot data from its registration-directed IGNYTE clinical trial cohort in anti-PD1 failed cutaneous melanoma and provides a program update on RP2 and RP3:
0
2
6
RT @Replimune: $REPL announces positive interim snapshot data from its registration-directed IGNYTE clinical trial cohort in anti-PD1 faile….
ir.replimune.com
RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%,...
0
5
0
Nice treat for @jitcancer readers! Neoadj CSCC @DrNeilGross , Seq of aPD-1 and BRAF/MEKi in melanoma Dr. Atkins @LombardiCancer, Harmonal therapies in females overcome ICB myocarditis @Chunrulin2 @MDAndersonNews , Oncometabolite D-2HG impairs T cell function @mela927 @harvardmed.
The latest edition of the #JITC Reading List is out. Social Media Editor Dr. Praveen K. Bommareddy (@Praveen_IO) selects articles that add value to what readers find in the Journal for ImmunoTherapy of Cancer. Enjoy articles from the #immunotherapy field
0
0
7
Looking forward to present! Oncolytic immunotherapy #biomarkers and#SITC22.
0
1
4